{"id":34216,"date":"2025-05-27T12:57:02","date_gmt":"2025-05-27T04:57:02","guid":{"rendered":"https:\/\/flcube.com\/?p=34216"},"modified":"2025-05-27T12:57:03","modified_gmt":"2025-05-27T04:57:03","slug":"bio-thera-solutions-terminates-bat3306-trial-amid-biosimilar-policy-shifts","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34216","title":{"rendered":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts"},"content":{"rendered":"\n<p>Guangzhou-based biotech Bio-Thera Solutions (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) announced the termination of a multi-center, randomized, double-blinded Phase I\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.<\/p>\n\n\n\n<p><strong>Regulatory Policy Shifts<\/strong><br>Recent communications from the FDA and the EMA\u2019s April 2025 reflection paper indicate that efficacy comparison studies are no longer essential for most biosimilar product approvals in the U.S. and EU. This shift has prompted companies to reassess their clinical trial strategies for biosimilar products.<\/p>\n\n\n\n<p><strong>Industry Response<\/strong><br>Globally, two companies developing pembrolizumab biosimilars have already halted their Phase III efficacy comparison trials. Formycon AG removed the Phase III trial results from its market filing, relying instead on Phase I and analytical data. Sandoz AG announced plans to streamline its Phase III trial for a pembrolizumab biosimilar in untreated metastatic non-squamous NSCLC patients.<\/p>\n\n\n\n<p><strong>Bio-Thera&#8217;s Decision<\/strong><br>After careful consideration, Bio-Thera concluded that the BAT3306-002 study is no longer necessary for BAT3306\u2019s regulatory review in the U.S. and EU. The company will continue to engage closely with regulatory authorities and will prudently assess the latest biosimilar evaluation policies to determine the future path for the BAT3306 project.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/688177_20250523_E0YY.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688177_20250523_E0YY.\"><\/object><a id=\"wp-block-file--media-aa345100-626e-41c2-9fd8-229893e01364\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/688177_20250523_E0YY.pdf\">688177_20250523_E0YY<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/688177_20250523_E0YY.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aa345100-626e-41c2-9fd8-229893e01364\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[289,43,1055],"class_list":["post-34216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bio-thera-solutions","tag-biosimilars","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase I\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts\" \/>\n<meta property=\"og:description\" content=\"Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase I\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T04:57:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T04:57:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts\",\"datePublished\":\"2025-05-27T04:57:02+00:00\",\"dateModified\":\"2025-05-27T04:57:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2708.webp\",\"keywords\":[\"Bio-Thera Solutions\",\"Biosimilars\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34216#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34216\",\"name\":\"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2708.webp\",\"datePublished\":\"2025-05-27T04:57:02+00:00\",\"dateModified\":\"2025-05-27T04:57:03+00:00\",\"description\":\"Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase I\\\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34216\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2708.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2708.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts - Insight, China&#039;s Pharmaceutical Industry","description":"Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase I\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34216","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts","og_description":"Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase I\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.","og_url":"https:\/\/flcube.com\/?p=34216","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-27T04:57:02+00:00","article_modified_time":"2025-05-27T04:57:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts","datePublished":"2025-05-27T04:57:02+00:00","dateModified":"2025-05-27T04:57:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34216"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp","keywords":["Bio-Thera Solutions","Biosimilars","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34216#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34216","url":"https:\/\/flcube.com\/?p=34216","name":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34216#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34216#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp","datePublished":"2025-05-27T04:57:02+00:00","dateModified":"2025-05-27T04:57:03+00:00","description":"Guangzhou-based biotech Bio-Thera Solutions (SHA: 688177) announced the termination of a multi-center, randomized, double-blinded Phase I\/III study evaluating BAT3306 combined with chemotherapy versus Keytruda combined with chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). This decision follows recent updates from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding biosimilar product approvals.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34216"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34216#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp","width":1080,"height":608,"caption":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Terminates BAT3306 Trial Amid Biosimilar Policy Shifts"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2708.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34216\/revisions"}],"predecessor-version":[{"id":34219,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34216\/revisions\/34219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34218"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}